<DOC>
	<DOCNO>NCT01033097</DOCNO>
	<brief_summary>This study ass safety efficacy DNK333 patient atopic dermatitis suffering pruritus , require systemic treatment disease .</brief_summary>
	<brief_title>Safety Efficacy DNK333 Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>Male female atopic dermatitis patients,18 60 year age inclusive , fulfill follow criterion : Requirement systemic therapy Itch VAS score high 50 mm EASI score high 8 Women childbearing potential willing use two highly effective method contraception allow study . Similarly , men willing use two acceptable method contraception allow study . Any systemic immunosuppressive treatment and/or phototherapy within 4 week prior first dose . Use systemic antihistamine topical corticosteroid within one week prior first dose duration treatment period . Any topical oral treatment atopic dermatitis ( except emollient prescribe investigator ) within 2 week prior first dose also exclude . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>inflammatory skin disease</keyword>
	<keyword>itch</keyword>
	<keyword>eczema</keyword>
</DOC>